JP2008531613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531613A5 JP2008531613A5 JP2007557357A JP2007557357A JP2008531613A5 JP 2008531613 A5 JP2008531613 A5 JP 2008531613A5 JP 2007557357 A JP2007557357 A JP 2007557357A JP 2007557357 A JP2007557357 A JP 2007557357A JP 2008531613 A5 JP2008531613 A5 JP 2008531613A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- tetradecylcarbamoyl
- pharmaceutical composition
- alkyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- JXQJBWXQMIFZIJ-MUMRKEEXSA-N (2r)-2-amino-3-[(dimethylamino)methyl]-4-oxo-4-(tetradecylamino)butanoic acid Chemical compound CCCCCCCCCCCCCCNC(=O)C(CN(C)C)[C@@H](N)C(O)=O JXQJBWXQMIFZIJ-MUMRKEEXSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 claims 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 claims 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Chemical group CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000090A ITRM20050090A1 (it) | 2005-03-02 | 2005-03-02 | Derivati dell'acido ammino-butanoico inibitore della cpt. |
PCT/EP2006/001290 WO2006092204A1 (en) | 2005-03-02 | 2006-02-13 | Derivatives of aminobutanoic acid inhibiting cpt |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008531613A JP2008531613A (ja) | 2008-08-14 |
JP2008531613A5 true JP2008531613A5 (US07981874-20110719-C00313.png) | 2009-04-02 |
Family
ID=36090946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007557357A Withdrawn JP2008531613A (ja) | 2005-03-02 | 2006-02-13 | Cptを阻害するアミノブタン酸誘導体 |
Country Status (15)
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2927045A1 (en) * | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
US8410150B2 (en) | 2007-03-09 | 2013-04-02 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
CA2694724C (en) | 2007-08-01 | 2017-09-12 | University Health Network | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
WO2009132979A1 (en) * | 2008-04-29 | 2009-11-05 | F. Hoffmann-La Roche Ag | 4-trimethylammonio-butyrates as cpt2 inhibitors |
ES2507089T3 (es) | 2008-04-29 | 2014-10-14 | F. Hoffmann-La Roche Ag | Derivados del ácido 4-dimetilaminobutírico |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1299266B1 (it) * | 1998-05-15 | 2000-02-29 | Sigma Tau Ind Farmaceuti | Inibitori reversibili della carnitina palmitoil trasferasi |
US6822115B2 (en) * | 1999-06-30 | 2004-11-23 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid |
US8410150B2 (en) | 2007-03-09 | 2013-04-02 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
-
2005
- 2005-03-02 IT IT000090A patent/ITRM20050090A1/it unknown
-
2006
- 2006-02-13 CN CNA2006800065461A patent/CN101133019A/zh active Pending
- 2006-02-13 MX MX2007009007A patent/MX2007009007A/es not_active Application Discontinuation
- 2006-02-13 CA CA002599165A patent/CA2599165A1/en not_active Abandoned
- 2006-02-13 JP JP2007557357A patent/JP2008531613A/ja not_active Withdrawn
- 2006-02-13 KR KR1020077022098A patent/KR20070114197A/ko not_active Application Discontinuation
- 2006-02-13 AU AU2006220097A patent/AU2006220097B2/en not_active Ceased
- 2006-02-13 WO PCT/EP2006/001290 patent/WO2006092204A1/en active Application Filing
- 2006-02-13 EA EA200701868A patent/EA200701868A1/ru unknown
- 2006-02-13 US US11/815,068 patent/US20080161395A1/en not_active Abandoned
- 2006-02-13 SG SG201001512-1A patent/SG159569A1/en unknown
- 2006-02-13 EP EP06706901A patent/EP1853556A1/en not_active Withdrawn
- 2006-02-13 BR BRPI0607558-4A patent/BRPI0607558A2/pt not_active IP Right Cessation
- 2006-02-15 TW TW095105107A patent/TW200640842A/zh unknown
- 2006-02-28 AR ARP060100732A patent/AR052677A1/es not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5373405B2 (ja) | 選択的アンドロゲン受容体モジュレーター | |
JP6595078B2 (ja) | アミノカルボニルカルバメート化合物 | |
AR047972A1 (es) | Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas. | |
JP2015516420A5 (US07981874-20110719-C00313.png) | ||
JP2008531613A5 (US07981874-20110719-C00313.png) | ||
NO20054775L (no) | Biaryl-substituerte triazoler som natriumkanalblokkere | |
KR20080106539A (ko) | 중수소화 카테콜아민 유도체 및 이를 포함하는 의약품 | |
JP2014505017A5 (US07981874-20110719-C00313.png) | ||
JP6200603B2 (ja) | 化学療法剤としてのβ置換βアミノ酸および類似体 | |
MA32108B1 (fr) | Derives d'indazole | |
WO2011089529A4 (en) | Salicylate fatty acid derivatives | |
RU2017141446A (ru) | Энантиомеры 2-гидроксипроизводных жирных кислот | |
RU2638549C2 (ru) | Производное циклического амина и его фармацевтическое применение | |
JP2009520010A5 (US07981874-20110719-C00313.png) | ||
JP7265817B2 (ja) | 甲状腺ホルモン受容体アゴニスト特性を有する肝臓標的化合物及びその医薬組成物 | |
WO2008094912B1 (en) | Substituted gamma lactams as therapeutic agents | |
US9937139B2 (en) | β-substituted γ-amino acids and analogs as chemotherapeutic agents | |
WO2009141079A1 (de) | Neue [f-18]-markierte l-glutaminsäure- und l-glutaminderivative (ii), ihre verwendung sowie verfahren zu ihrer herstellung | |
RU2013113301A (ru) | Замещенные 2-оксо- и 2-тиоксо-дигидрохинолин-3-карбоксамиды в качестве модуляторов kcnq2/3 | |
WO2009119858A1 (ja) | ベンゼン化合物及びその医薬用途 | |
JP2007536318A5 (US07981874-20110719-C00313.png) | ||
US20120016155A1 (en) | Diastereoisomers of hypophosphorous acid derivatives | |
CN103827111A (zh) | N-杂环取代酰胺衍生物 | |
JP2014524411A5 (US07981874-20110719-C00313.png) | ||
JP6642422B2 (ja) | 環状アミン誘導体及びその医薬用途 |